Related Experiment Video
Updated: Aug 9, 2025

CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy
Published on: March 12, 2018
CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model
Sheng Cui1, Yoo Jin Shin1, Xianying Fang1
1Transplantation Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract:
The objective of this study was to investigate whether CRISPR/Cas9-mediated suppression of A4GALT could rescue phenotype of Fabry disease nephropathy (FDN) using human induced pluripotent stem cells (hiPSCs) derived kidney organoid system. We generated FDN patient-derived hiPSC (CMC-Fb-002) and FD-specific hiPSCs (GLA-KO) by knock-out (KO) of GLA in wild-type (WT) hiPSCs using CRISPR/Cas9. We then performed A4GALT KO in both CMC-Fb-002 and GLA-KO to make Fb-002-A4GALT-KO and GLA/A4GALT-KO, respectively. Using these hiPSCs, we generated kidney organoids and compared alpha-galactosidase-A enzyme (α-GalA) activity, globotriaosylceramide (Gb-3) deposition, and zebra body formation under electron microscopy (EM). We also compared mRNA expression levels using RNA-seq and qPCR. Generated hiPSCs showed typical pluripotency markers without chromosomal disruption. Expression levels of GLA in CMC-Fb-002 and GLA-KO and expression levels of A4GALT in Fb-002-A4GALT-KO and GLA/A4GALT-KO were successfully decreased compared to those in WT-hiPSCs, respectively. Generated kidney organoids using these hiPSCs expressed typical nephron markers. In CMC-Fb-002 and GLA-KO organoids, α-GalA activity was significantly decreased along with increased deposition of Gb-3 in comparison with WT organoids. Intralysosomal inclusion body was also detected under EM. However, these disease phenotypes were rescued by KO of A4GALT in both GLA/A4GALT-KO and Fb-002-A4GALT-KO kidney organoids. RNA-seq showed increased expression levels of genes related to FDN progression in both GLA-mutant organoids compared to those in WT. Such increases were rescued in GLA/A4GALT-KO or Fb-002-A4GALT-KO organoids. CRISPR/Cas9 mediated suppression of A4GALT could rescue FDN phenotype. Hence, it can be proposed as a therapeutic approach to treat FDN.
Insights
CRISPR/Cas9 gene editing successfully suppressed A4GALT, rescuing Fabry disease nephropathy (FDN) phenotypes in kidney organoids. This approach offers a potential therapeutic strategy for FDN.
Area of Science:
- Biotechnology
- Genetics
- Stem Cell Biology
Background:
- Fabry disease nephropathy (FDN) is a genetic disorder characterized by alpha-galactosidase-A deficiency, leading to globotriaosylceramide accumulation.
- Current treatments for FDN are limited, necessitating the development of novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential of CRISPR/Cas9-mediated suppression of A4GALT to rescue FDN phenotypes.
- To utilize human induced pluripotent stem cells (hiPSCs)-derived kidney organoids as a model system for FDN research.
Main Methods:
- Generated FDN patient-derived hiPSCs and GLA-knockout (KO) hiPSCs.
- Performed A4GALT KO in both FDN and GLA-KO hiPSCs using CRISPR/Cas9.
- Developed kidney organoids from engineered hiPSCs and analyzed alpha-galactosidase-A (α-GalA) activity, globotriaosylceramide (Gb-3) deposition, and gene expression.
Main Results:
- Engineered hiPSCs maintained pluripotency without chromosomal abnormalities.
- A4GALT KO successfully reduced A4GALT expression in kidney organoids.
- CRISPR/Cas9-mediated A4GALT suppression rescued FDN phenotypes, including Gb-3 deposition and normalized gene expression patterns in kidney organoids.
Conclusions:
- CRISPR/Cas9-mediated A4GALT suppression effectively rescues FDN phenotypes in a hiPSC-derived kidney organoid model.
- Targeting A4GALT presents a promising therapeutic avenue for treating Fabry disease nephropathy.

